Skip to main content
. 2019 Apr 13;9(8):2380–2394. doi: 10.7150/thno.29724

Figure 1.

Figure 1

Clinical significance of SIRT6 signaling in human colorectal cancer. (A-D) SIRT6 is down-regulated in colorectal cancer. (A) Immunohistochemical of SIRT6 level in colotectal cancer tissues (CA) and paired non-cancerous tissues (NCA). (100×). (B-D) Down-regulation of SIRT6 in patient samples from our hospital and from Oncomine database (TCGA and Skrzypczak). (B) The logarithmic scale 2-ΔΔCt was carried out to show the relative SIRT6 expression of patient samples. (C and D) Box plot of SIRT6 mRNA Log2 expression levels was evaluated in Oncomine database. (E-G) Low SIRT6 levels in CRC patients correlates with poor prognosis. (E) Representative immunohistochemical staining in colon cancer tissues with different degree of SIRT6 expression. Number of positive cells: (-) <10%; (±) 10-30%; (+) 30-60%; (++)>60%. (F and G) Kaplan-Meier curves of CRC patients with high versus low expression of SIRT6 (n=50; p< 0.05, log-rank test). (H-K) Inverse correlation between SIRT6 and p-Akt or p-FoxO3a expression in human colon cancer. (H) Immunohistochemical stainings of SIRT6, p-Akt and p-FoxO3a in colon cancer tissue. Three representative cases are shown. (I) Total IHC score of SIRT6, p-FoxO3a and p-Akt in colon cancer tissue and non-cancerous tissue (n=50). *P<0.05. (J and K) The percentages of CRC specimens with low or high p-FoxO3a or p-Akt levels and their relationship to SIRT6 expression.